190 related articles for article (PubMed ID: 34962991)
1. Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment.
Honap S; Meade S; Spencer A; Pavlidis P; Luber RP; Calonje E; Rashidghamat E; Bunker CB; Lewis F; Irving PM
J Crohns Colitis; 2022 Jun; 16(5):822-834. PubMed ID: 34962991
[TBL] [Abstract][Full Text] [Related]
2. Genital Granulomatosis in Male and Female Patients With Crohn's Disease: Clinical Presentation and Treatment Outcomes.
Dederichs F; Iesalnieks I; Sladek M; Tzivinikos C; Hansen R; Muñoz C; Pavli P; Cavicchi M; Abitbol V; Rahier JF; Vavricka S; Katsanos K; Domènech E;
J Crohns Colitis; 2018 Jan; 12(2):197-203. PubMed ID: 29029098
[TBL] [Abstract][Full Text] [Related]
3. Ano-genital Granulomatosis and Crohn's Disease: A Case Series of Males Presenting with Genital Lymphoedema.
Alexakis C; Gordon K; Mellor R; Chong H; Mortimer P; Pollok R
J Crohns Colitis; 2017 Apr; 11(4):454-459. PubMed ID: 27683802
[TBL] [Abstract][Full Text] [Related]
4. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
5. Crohn's disease of the vulva: A prospective study.
Bhoyrul B; Lyon C
J Gastroenterol Hepatol; 2018 Dec; 33(12):1969-1974. PubMed ID: 29845642
[TBL] [Abstract][Full Text] [Related]
6. Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
[TBL] [Abstract][Full Text] [Related]
7. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
8. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
9. Association between orofacial granulomatosis and Crohn's disease in children: systematic review.
Lazzerini M; Bramuzzo M; Ventura A
World J Gastroenterol; 2014 Jun; 20(23):7497-504. PubMed ID: 24966621
[TBL] [Abstract][Full Text] [Related]
10. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
Ding NS; McDonald JAK; Perdones-Montero A; Rees DN; Adegbola SO; Misra R; Hendy P; Penez L; Marchesi JR; Holmes E; Sarafian MH; Hart AL
J Crohns Colitis; 2020 Sep; 14(8):1090-1102. PubMed ID: 32119090
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
12. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
13. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study.
Levine A; Turner D; Pfeffer Gik T; Amil Dias J; Veres G; Shaoul R; Staiano A; Escher J; Kolho KL; Paerregaard A; Martin de Carpi J; Veereman Wauters G; Koletzko S; Shevah O; Finnby L; Sladek M
Inflamm Bowel Dis; 2014 Feb; 20(2):278-85. PubMed ID: 24390062
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
15. Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth L; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853
[TBL] [Abstract][Full Text] [Related]
16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous manifestations of metastatic Crohn's disease.
Schneider SL; Foster K; Patel D; Shwayder T
Pediatr Dermatol; 2018 Sep; 35(5):566-574. PubMed ID: 29952016
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine for induction of remission in Crohn's disease.
McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
